Back Login to subscribe 🔔 Set Alert

MRK Merck & Co., Inc.

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls	93.06%
	Moderna And Merck Present 5-Year Data For Intismeran Autogene in Combination With KEYTRUDA In Patients With High-Risk Stage III/IV Melanoma	93.87%
	Merck Announces FDA Breakthrough Therapy Designation For Calderasib, An Investigational Oral Specific KRAS G12C Inhibitor, In Combination With Keytruda	79.49%
	Dow Jones Hits Record Highs, DELL Jumps 15%: Stock Market Today	57.91%
	European Medicines Agency's Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Approval Of Merck's KEYTRUDA In Combination With Padcev To Treat Resectable Muscle-Invasive Bladder Cancer	62.45%
	National Advertising Review Board Refers Merck Animal Health To FTC And FDA For Bravecto Quantum Dosing Claims	63.11%
	Exelixis Enters Clinical Development Collaboration With Merck For Its KEYTRUDA QLEX Injection In Combination With Zanzalintinib In The STELLAR-316 Phase 3 Trial	57%
	U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide	89.68%
	Merck Announces Pivotal Phase 3 TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints Of OS And PFS In Certain Patients With Endometrial Cancer	94.07%
	Why Is Regeneron Stock Sinking Monday?	89.35%

1
2
›